INTRODUÇÃO E OBJETIVOS: Distúrbios miccionais são freqüentes em pacientes com doença de Parkinson, mas sua associação com parâmetros como idade do paciente, gênero, gravidade do comprometimento neurológico e duração da doença não é bem conhecida. Neste estudo, avaliamos prevalência e características dos sintomas miccionais em pacientes com doença de Parkinson e examinamos sua associação com parâmetros clínicos com potencial impacto sobre a disfunção miccional. MÉTODOS: Avaliamos prospectivamente 110 pacientes, incluindo 84 homens (76,4%) e 26 mulheres (23,6%), com idade média de 61,8 ± 9,6 anos. Os critérios de inclusão foram doença de Parkinson idiopática e idade acima de 40 anos. Pacientes com outras doenças neurológicas, história de cirurgia e radioterapia pélvica foram excluídos. A duração média da doença foi 12,3 ± 7,2 anos. O comprometimento neurológico foi avaliado pelas escalas Hoehn-Yahr (HY) e Escala Unificada de Avaliação da Doença de Parkinson (UPDRS). Os sintomas miccionais foram avaliados pelo questionário da Sociedade Internacional de Continência para Homens, incluindo uma questão de qualidade de vida relacionada a sintomas miccionais. Consideramos sintomáticos os pacientes que queriam tratamento para sua disfunção miccional. Estes foram avaliados com análise de urina, creatinina sérica, PSA, ultra-sonografia do aparelho urinário e urodinâmica. Avaliamos a associação da disfunção miccional com idade, gênero, tempo de duração da doença, grau de comprometimento neurológico, impacto na qualidade de vida e achados urodinâmicos. RESULTADOS: A avaliação neurológica demonstrou média de 3,0 ± 0,8 na escala de HY e 70,0 ± 31,1 na escala de UPDRS. A média do escore miccional foi de 11,9 ± 9,3 e os sintomas mais comuns foram noctúria em 89 (80,9%) pacientes, urgência em 40 (36,3%) e aumento da freqüência miccional em 39 (35,4%) pacientes. A duração média dos sintomas miccionais foi de 3,8 ± 3,4 anos. A prevalência da disfunção miccional aumentou significativamente com o aumento no grau de comprometimento neurológico, mas não com a idade nem com a duração da doença. A qualidade de vida relacionada aos sintomas miccionais foi afetada pela severidade da disfunção miccional e os sintomas de freqüência e noctúria são os de pior impacto na qualidade de vida. Sessenta e três pacientes (57,2%) eram sintomáticos e 54 (43 homens e 11 mulheres) completaram a avaliação. Os pacientes sintomáticos apresentaram disfunção neurológica mais severa (HY médio 3,2 ± 0,8 vs 2,8 ± 0,9 para os assintomáticos; p=0,035). A idade, a duração da doença e dos sintomas miccionais não diferiram entre sintomáticos e assintomáticos. O volume médio da próstata foi 30,3 ± 10,7 cc. Os achados urodinâmicos foram obstrução infravesical em 38 (70,3%) pacientes, hiperatividade detrusora em 27 (50,0%), e hipocontratilidade detrusora em seis (11,1%) pacientes. O grau de comprometimento neurológico não se associou com nenhum padrão urodinâmico. Na comparação entre homens e mulheres sintomáticos a única diferença observada foi a maior gravidade dos sintomas de esvaziamento nos homens. CONCLUSÕES: A maior parte dos pacientes com doença de Parkinson apresenta disfunção miccional significativa e a gravidade da doença neurológica é o principal fator preditivo para a ocorrência de disfunção miccional. Obstrução infravesical e hiperatividade detrusora são os achados urodinâmicos mais comuns, mas não estão associados com o grau de comprometimento neurológico. Homens e mulheres são similarmente afetados pelos sintomas miccionais e não demonstraram distinção quanto aos achados urodinâmicos. / INTRODUCTION AND OBJECTIVES: Voiding dysfunction often occurs in patients with Parkinsons disease, but its association with patients age, gender, degree of neurological impairment, and disease duration is not fully known. In this study, we assessed the prevalence and characteristics of lower urinary tract symptoms (LUTS) in patients with Parkinson\'s disease and examined their association with those clinical parameters that could have an impact on voiding dysfunction. METHODS: We prospectively evaluated 110 patients, of which 84 were men (76.4%) and 26 were women (23.6%), with a mean age of 61.8 ± 9.6 years. The inclusion criteria were: idiopathic Parkinsons disease and age > 40 years. Patients with other neurological diseases and history of pelvic surgery and radiotherapy were excluded. Mean duration of the disease was 12.3 ± 7.2 years. The neurological impairment was assessed by the Hoehn-Yahr scale (HY) and the Unified Parkinson Disease Rating Scale (UPDRS). Lower urinary tract symptoms were assessed by the International Continence Society male questionnaire, which included a question about quality of life related to LUTS. Those patients who wanted to be treated for their voiding dysfunction were considered as symptomatic. They underwent urine analysis, serum creatinine measurement, PSA, urinary tract imaging and urodynamic study. We examined the association between voiding dysfunction and age, gender, disease duration, degree of neurological impairment, impact on quality of life, and urodynamic findings. RESULTS: The neurological assessment showed a mean HY score of 3.0 ± 0.8 and a mean UPDRS score of 70.0 ± 31.1. Mean LUTS score was 11.9 ± 9.3, and the most prevalent symptoms were nocturia in 89 (80.9%) patients, urgency in 40 (36.3%), and frequency in 39 (35.4%). Mean duration of LUTS was 3.8 ± 3.4 years. The prevalence of voiding dysfunction increased significantly with the degree of neurological impairment, but not with patients age or disease duration. Quality of life was affected by the severity of the voiding dysfunction, and the symptoms with the worst impact on quality of life were frequency and nocturia. Sixty-three patients (57.2%) were symptomatic and 54 (43 men and 11 women) concluded the evaluation. Symptomatic patients had more severe neurological dysfunction (mean HY 3.2 ± 0.8 vs 2.8 ± 0.9 for asymptomatic patients; p=0.035). Symptomatic and asymptomatic patients did not differ as to age, disease duration and LUTS. Mean prostate volume was 30.3 ± 10.7 cc. The urodynamic findings were bladder outlet obstruction in 38 (70.3%) patients, detrusor overactivity in 27 (50.0%), and detrusor underactivity in 6 (11.1%). The degree of neurological impairment was not associated with any urodynamic pattern. The only difference observed between symptomatic men and women was that the voiding symptoms were more severe in men. CONCLUSIONS: Most patients with Parkinsons disease have significant voiding dysfunction, and the severity of the neurological disease is the main predictive factor for the occurrence of voiding dysfunction. Bladder outlet obstruction and detrusor overactivity are the most common urodynamic findings, although not associated with the degree of neurological impairment. Men and women are equally affected by LUTS and show similar urodynamic findings.

Chronic pelvic pain (CPP) is defined as constant or intermittent lower, cyclical or non-cyclical abdominal pain of at least six months’ duration. In the United Kingdom, over 1 million women suffer from CPP, with an estimated annual healthcare cost above £150 million. The aetiology of CPP is unknown in up to 50% of women, and in the remainder, the symptoms of CPP is associated with endometriosis, pelvic adhesions, irritable bowel syndrome or painful bladder syndrome. CPP is often accompanied by painful periods, pain during sexual intercourse and defaecation. Fatigue, sleep disturbances and depression are also common among this group of women. CPP asserts a heavy emotional, social and economic burden. Standard treatments such as hormonal and analgesic regimens are often associated with unacceptable side effects, even if helpful for the pain, underlining an urgent need for a satisfactory treatment. The meridian balanced method (BM) electro-acupuncture (EA) treatment (acupuncture needling + traditional Chinese medicine health consultation [TCM HC]) may be effective in managing CPP symptoms. Thus, I have completed a pilot study comprising of a three-armed randomised controlled trial (RCT), using a mixed methods research (MMR) approach, to assess the feasibility of a future large-scale RCT to determine the effectiveness of the meridian BMEA treatment on CPP in women. My hypothesis is that it is feasible to conduct such a large-scale RCT for CPP in women. The primary objectives were to determine recruitment and retention rates. The secondary objectives were to evaluate the, acceptability of the methods of recruitment, randomisation, interventions and assessment tools and any signals of effectiveness of the interventions. Thirty (30) women with CPP were randomised into three groups: BMEA treatment, TCM HC, or National Health Service standard care (NHS SC) group. The effects of my interventions were assessed by validated pain, physical and emotional functioning questionnaires, completed at weeks 0, 4, 8 and 12 of the study. Semi-structured telephone interviews and focus group discussions to explore participants’ experience of the study were conducted. Of the 59 women who were referred to the study, 30 women (51%) were randomised. There was a statistically significant difference in retention rates between the three groups. The retention rates were 80% (95% CI 74-96), in the BMEA treatment group, 53 % (95% CI 36- 70) in the TCM HC group and 87% (95% CI 63-90) in the NHS SC group. (Chi-square test, p=0.08) The attendance rates of the BMEA treatment group were 90% compared to 56% in the TCM HC group. There was a statistically significant difference (Mann-Whitney test, p=0.023) in attendance between the two intervention groups. Telephone interviews regarding the acceptability of the methods of recruitment, randomisation, assessment tools and interventions were positive. No adverse effects that were directly related to BMEA treatments were reported or observed. A higher proportion of the BMEA treatment group achieved clinical significance in the VAS-pain, BPI-pain severity, interference, and sleep scores, when compared to the other two groups. Due to small sample sizes, there was insufficient power to show statistically significant difference. (Fishers Exact Test, p=1.0) Analyses of the questionnaire data per group showed statistically significant differences in the following: the BMEA treatment group experienced less in pain at weeks 4 (p=0.01) and 8 (p=0.005); less helplessness (p=0.03) and their anxiety and depression scores declined at week 4 (p=0.04). The NHS SC group also reported less pain at week 4 (p=0.04). However, this group scored higher in anxiety and depression at weeks 8 and 12 (p=0.04). No statistically significant differences were achieved between the three groups at baseline, weeks 4, 8 and 12 in all scores. The therapeutic benefits gained by the TCM HC group were less compared to those of the BMEA treatment group, but better when compared to the NHS SC group. The BMEA treatment and TCM HC groups showed lower scores in anxiety and depression while the NHS SC group showed higher scores in anxiety and depression. The NHS SC group also tended to ruminate and magnify their problems as well as feeling more helpless than the other two groups. The three key themes that emerged from thematic analysis of focus group discussions were the “whole person effects” where participants reported an improvement in pain, sleep and a general sense of wellbeing in the two intervention groups; the “experience of standard care” and “impact of living with CPP”. In conclusion, the results of my pilot study are supportive of the feasibility of a future large-scale study. There were signals of effectiveness of interventions but the sample size was too small to make a definitive conclusion.

Les travaux présentés dans cette thèse concernent le développement d'un outil d'analyse multiparamétrique pour la quantification de biomarqueurs urinaires du cancer de la vessie.La première partie des travaux de recherche a pour objectif la sélection de marqueurs pour le diagnostic et la récidive des tumeurs urothéliales. Une première étude a permis l'évaluation de la sélectivité de marqueurs candidats dans des échantillons urinaires de patients atteints de cancer de la vessie. Cinq des vingt marqueurs initiaux ont été sélectionnés pour leur performance diagnostique, définissant le Panel 1 : VEGF, MMP9, IL8, PTGS2 et EN2. Une seconde étude a été réalisée afin d'évaluer le potentiel de marqueurs et de paramètres cliniques pour le diagnostic de la récidive des tumeurs urothéliales. Les échantillons urinaires évalués provenaient donc de patients présentant une récidive du cancer de la vessie et de patients ne présentant pas de récidive. Le Panel 2 a ainsi été défini, basé sur le modèle de régression multiple le plus performant. Il comprend les paramètres cliniques et moléculaires suivants : nombre de récidives antérieures, nombre de thérapies par BCG, stade de la tumeur au moment du diagnostic, CDH1, IL8, ErbB2, IL6, EN2 et VEGF.La seconde partie concerne le développement d'un test multiparamétrique pour la quantification des marqueurs sélectionnés. Il s'agit d'une plateforme automatisée, à haut-débit et sous un format de plaque de microtitration 96-puits. La méthode de quantification choisie est un immunoessai de type sandwich sous la forme de puce à protéines. Le développement de la plateforme a débuté avec le Panel 1 dont trois des cinq marqueurs (VEGF, MMP9 et IL8) ont été intégrés avec succès. Suite à la seconde étude de sélection de marqueurs, le développement de l'immunoessai multiparamétrique a été orienté vers le Panel 2. À l'exception du marqueur EN2, nécessitant une configuration d'immunoessai différente, tous les marqueurs du Panel 2 ont pu être intégrés à la plateforme / The work reported in this thesis focuses on the development of a multiplex analytical tool for the quantification of selected bladder cancer urinary biomarkers.The aim of the first part of this work is the selection of urinary biomarkers for the diagnosis and recurrence of urothelial tumors. A first study evaluated the selectivity of candidate markers in urine samples of bladder cancer patients. Five of the twenty initial markers were selected for their diagnostic performance. They define Panel 1: VEGF, MMP9, IL8, PTGS2 and EN2. A second study was then conducted to assess the potential of urinary markers and clinical parameters for the diagnosis of bladder cancer recurrence. Two types of urine samples were thus evaluated: samples from recurrent bladder cancer patients and samples from bladder cancer patients without recurrence. Panel 2 was then defined based on the best performing multivariate regression model. It includes the following clinical and molecular parameters: number of past recurrences, number of BCG therapies, tumor stage at diagnosis, CDH1, IL8, ErbB2, IL6, EN2 and VEGF.The second part involves the development of a multiplex test for the quantification of the selected markers. It is a high-throughput automated platform in a 96-well microtiter plate format. It was designed as a multiplex sandwich immunoassay based on a protein microarray. The platform development began with Panel 1 for which three of the five markers (VEGF, MMP9 and IL8) were successful integrated into a multiplex immunoassay. The end of the second marker selection study marked the development transition from Panel 1 to Panel 2. With the exception of EN2, requiring a different immunoassay configuration, all the Panel 2 markers were integrated into the platform

BPH¡]Benign prostate hyperplasia¡^is one of the most common chronic diseases in aging male around the globe. TURP¡]Transurethral Resection of Prostate¡^remains the gold standard procedure of choice in BPH treatment. But limited literatures regarding the late complication of TURP was available. For understanding the long term follow up result after TURP, and predict the risk factors for re-intervention, we accessed the hospital claims for TURP from the National Health Insurance database, utilizing data from 2001 to 2007 , in 2001, 2002, 2003 TURP cases, we followed each cohort for 5 years to evaluate the late complications. We also examined the association between the characteristics of patient, hospital and the long term prognosis. In this study we found that from 2001to 2003, totally 1,225 patients under went TURP surgery, with the average age 71.52 ¡Ó 7.65 years (47-94 years). Among these cases, 140 patients (11.43%) experienced secondary surgery. Of the 140 secondary surgery patients, 71 received a secondary TURP, 35 received urethral stricture related surgery and 34 received bladder neck contracture related surgery. The study revealed both the characteristics of the patient and the hospital did not show significantly effect to the long term prognosis. In prediction the risk factors of the secondary surgery, the logistic regression analysis revealed those hospitals located at the central part of Taiwan compared to those at northern part of Taiwan showed a relative risk of 0.58, a significant trend of lower risk for secondary surgery. Otherwise, except this geographic location difference, other characteristics of the patient and the hospital show no significantly risk to the post-TURP second surgery. Conclusion of our study, the result of TURP surgery in Taiwan was fairly equal to that in advanced countries. Patient comorbidity, treated in different level, ownership hospitals resulted no significant difference in post-TURP prognosis.

Das Harnblasenkarzinom (BCa) ist die zweithäufigste bösartige urologische Tumorerkrankung sowie die siebthäufigste tumorbedingte Todesursache bei Männern. Zur Senkung des erheblichen Rezidiv- und Progressionsrisikos oberflächlicher BCa kommen lokale Immun- oder Chemotherapeutika zum Einsatz, die jedoch starke Nebenwirkungen verursachen können bzw. ungenügende langfristige Effekte bewirken. Eine neuartige Therapieoption besteht in der gezielten Expressionshemmung von Genen, die den Tumorzellen einen Wachstumsvorteil vermitteln. Hierfür eignen sich besonders synthetische Nukleinsäuren wie Antisense-Oligodesoxynukleotide (AS-ODN) und small interfering RNAs (siRNAs). In der vorliegenden Arbeit wurde die Expressionshemmung des potenziellen Targetgens hTERT (humane Telomerase Reverse Transkriptase) mit AS-ODN und siRNAs in BCa-Zellen untersucht. Die Tumorspezifität der hTERT-mRNA-Expression konnte zunächst an tumor- und tumorfreien Gewebeproben von BCa-Patienten gezeigt werden. Die verwendeten AS-ODN reduzierten die hTERT-mRNA-Expression auf bis zu 40%, womit eine Verringerung der Telomeraseaktivität einherging. Die AS-ODN-Behandlung bewirkte des Weiteren eine konzentrationsabhängige Viabilitätsreduktion verschiedener BCa-Zelllinien sowie eine verminderte Zellkoloniebildungsrate. Diese antiproliferativen Effekte waren auf eine Apoptoseinduktion zurückzuführen. Durch eine Vorbehandlung von vier BCa-Zelllinien mit hTERT-AS-ODN konnten die zytotoxischen Effekte der für das BCa relevanten Chemotherapeutika Cisplatin, Mitomycin C und Gemcitabin signifikant verstärkt werden. Nach Untersuchung der AS-ODN-Wirkung in vitro erfolgte die Etablierung eines subkutanen Xenotransplantantmodells der Nacktmaus. Die Eignung einer intraperitonealen Applikation wurde mit fluoreszenzmarkierten AS-ODN belegt. In weiteren Zellkulturexperimenten kamen hTERT-siRNAs, als alternative Methode der Geninhibition, zum Einsatz. Die Reduktion der hTERT-mRNA-Expression auf 50% war mit der durch AS-ODN bewirkten Inhibition vergleichbar. Im Gegensatz zur AS-ODN-Behandlung induzierten siRNAs keine unmittelbare Apoptose. Eine Kombination der siRNAs mit Cisplatin und Mitomycin C bewirkte jedoch eine Verdopplung der Apoptoserate. Um die molekularen Mechanismen der Wirkung der nukleinsäurebasierten hTERT-Inhibitoren und den Einfluss targetunabhängiger Effekte zu untersuchen, wurden transkriptomweite Expressionsanalysen mittels Oligonukleotid-Microarrays durchgeführt. Hierbei zeigte sich, dass die AS-ODN-Behandlung vorwiegend zu einer gesteigerten Expression von Genen führte, die mit einer zellulären Stressantwort assoziiert sind (u.a. ATF3, EGR1, GADD45). Diese Expressionsmuster stimmten in hohem Maße mit denen überein, die durch Transfektion mit AS-ODN gegen andere Targets erhalten wurden. Diese Ergebnisse deuten auf eine, zumindest teilweise, durch off-Targeteffekte ausgelöste Wachstumshemmung hin. Die siRNA-Behandlungen gegen unterschiedliche Targets zeigten relativ geringe Übereinstimmungen in den Expressionsmustern und somit eine höhere Spezifität. Außerdem wurde erstmalig gezeigt, dass eine hTERT-Inhibition mit siRNAs zur trankriptionellen Hemmung der Onkogene EGFR und FOSL1 führt. Diese Daten sowie die Ergebnisse anderer Arbeitsgruppen deuten auf einen wechselseitigen Zusammenhang zwischen hTERT und EGFR in der Regulation der EGFR-stimulierten Proliferation von BCa-Zellen hin. Zusammenfassend lässt sich feststellen, dass hTERT als tumorspezifisch exprimierter und funktionell relevanter Faktor ein hervorragendes Target für eine nukleinsäurebasierte BCa-Therapieoption darstellt. Im Vergleich zu AS-ODN wirken siRNAs grundsätzlich targetspezifischer. Die therapeutische Wertigkeit der lokal applizierten Inhibitoren, insbesondere in Kombination mit herkömmlichen Chemotherapeutika, sollte in nachfolgenden Experimenten im Rahmen eines orthotopen BCa-Xenotransplantatmodells untersucht werden.

Objectifs: Les données provenant des centres de soins tertiaires suggèrent que le taux de mortalité péri-opératoire (MPO) après cystectomie notés pour les patients âgés (septuagénaires et octogénaires) n’excède pas celle des patients plus jeunes. Toutefois, les données provenant de la communauté démontrent un phénomène inverse. Spécifiquement, la MPO est plus élevés chez les ainés. Dans cette thèse nous allons présenter une réévaluation contemporaine du taux de MPO après cystectomie. Méthodes: Entre 1988 et 2006, 12722 cystectomies radicales pour le carcinome urothéliale de la vessie ont été enregistrées dans la banque de données SEER. Le taux de MPO a été évalué dans les analyses de régression logistique univariées et multivariées à 90 jours après cystectomie radicale. Les covariables incluaient: le sexe, l’ethnie, l’année de chirurgie, la région d’origine du patient ainsi que le grade et le stade de la tumeur. Résultats: Parmi tous les patients, 4480 étaient des septuagénaires (35.2%) et 1439 étaient des octogénaires (11.3%). Le taux de MPO à 90 jours était de 4% pour la cohorte entière vs. 2% pour les patients moins de 69 ans vs. 5.4% pour les septuagénaires vs. 9.2% pour les octogénaires. Dans les analyses de régression logistiques multivariées, les septuagénaires (OR=2.80; <0.001) et les octogénaires (OR=5.02; <0.001) avaient reçu un taux de MPO plus augmenté que les patients moins de 70 ans après une cystectomie radicale. Conclusion: Cette analyse épidémiologique basée sur les donnés le plus contemporaines démontre que l’âge avancée représente un facteur de risque pour un taux de MPO plus élevé. / Objective Data from tertiary care centers suggest that the perioperative mortality (POM) after radical cystectomy (RC) is not different in septuagenarian or octogenarian patients, compared to younger individuals. Conversely, population-based data state otherwise. We revisited this topic in a large contemporary population-based cohort. Methods Between 1988 and 2006, 12722 radical cystectomies were performed for urothelial carcinoma of the urinary bladder (UCUB) in 17 Surveillance, Epidemiology and End Results (SEER) registries. Of those 4480 were aged 70-79 and 1439 were 80 years and older. Univariable and multivariable logistic regression models tested 90-day mortality (90dM) after radical cystectomy. Covariates consisted of gender, race, year of surgery, SEER registry, histological grade and stage. Results Of all 12722 patients, 4480 (35.2%) were septuagenarian and 1439 (11.3%) were octogenarian. The overall 90dM rate was 4% for the entire population, 2% for patients aged 69 years or younger, 5.4% for septuagenarian patients and 9.2% for octogenarian patients. In multivariable logistic regression analyses, septuagenarian (OR= 2.80; <0.001) and octogenarian (OR= 5.02; <0.001) age increased the risk of 90dM after RC. Conclusions In this population-based analysis, POM was between 3 and 5-fold higher respectively in septuagenarian and octogenarian patients which is higher in tertiary care centers. This information needs to be included in informed consent considerations, specifically if RC will not be performed at a tertiary care center.

Das Harnblasenkarzinom (BCa) stellt in Deutschland die vierthäufigste Tumorneuerkrankung und die zehnthäufigste krebsbedingte Todesursache bei Männern dar. Nichtmuskelinvasive BCa werden organerhaltend aus der Blasenwand entfernt und zur Rezidiv- und Progressionsprophylaxe mittels intravesikaler Chemo- oder Immuntherapien behandelt. Trotz dieser adjuvanten Therapien, die mit starken Nebenwirkungen verbunden sein können, ist nur eine bedingte Minimierung des Rezidivrisikos möglich. Besonders im fortgeschrittenen Stadium weisen Harnblasenkarzinome eine schlechte Prognose auf. Obwohl das BCa eine chemosensitive Erkrankung darstellt, wird das Ansprechen auf lokale oder systemische Chemotherapien häufig durch auftretende Resistenzmechanismen limitiert. Daher stehen sowohl die Verbesserung konventioneller Chemotherapien als auch die Suche nach neuartigen Behandlungsstrategien im Fokus der experimentellen BCa-Forschung. Die Apoptose, eine Form des programmierten Zelltodes, ist ein essenzieller, streng regulierter biologischer Prozess, welcher der Aufrechterhaltung der Gewebshomöostase und der gezielten, entzündungsfreien Eliminierung geschädigter Zellen dient. Fehlregulationen in den Apoptosesignalwegen stellen ein zentrales Ereignis in der Tumorgenese dar und tragen außerdem zur Entstehung von Chemo- und Radiotherapieresistenzen bei. Eine wichtige Rolle in der Apoptoseregulation spielen die Mitglieder der BCL2- und der Inhibitor of Apoptosis Protein (IAP)-Familien, deren wichtigste antiapoptotische Vertreter BCL2, BCL-XL, XIAP und Survivin häufig in Tumoren, einschließlich des BCa, überexprimiert sind. Unter Verwendung von small interfering RNAs (siRNAs), synthetischen Nukleinsäurekonstrukten zur selektiven Geninhibition, wurde im Rahmen der Arbeit in vitro und in vivo untersucht, ob die Hemmung der Apoptoseinhibitoren BCL2, BCL-XL, XIAP und Survivin – allein und in Kombination mit Chemotherapie – eine Therapieoption zur Behandlung des BCa darstellen könnte. Da zur Tumorentstehung und -progression eine Vielzahl von genetischen Veränderungen beitragen, erscheint der Angriff eines einzelnen Zielgens unzureichend für eine effektive Tumortherapie. Aufgrund dessen wurde untersucht, ob durch simultane Reduktion der ausgewählten Apoptoseinhibitoren in BCa-Zellen stärkere wachstumsinhibitorische Effekte erzielt werden können. In der vorliegenden Arbeit wurde gezeigt, dass insbesondere die siRNA-vermittelte Hemmung von BCL-XL und Survivin in den BCa-Zelllinien EJ28 und J82 antiproliferative Effekte hervorruft und diese Tumorzellen gegenüber einer nachgeschalteten Chemotherapie mit Mitomycin C oder Cisplatin sensitiviert. Hingegen bewirkte sowohl die transiente als auch die stabile RNAi-induzierte Hemmung von BCL2 und XIAP in den untersuchten BCa-Monolayerzellkulturen, möglicherweise infolge kontinuierlicher Versorgung der Tumorzellen mit Sauerstoff und Nährstoffen, keine Reduktion des Tumorwachstums. Eine gegenüber den Einzelbehandlungen deutliche Verstärkung der antitumoralen und insbesondere der chemosensitivierenden Effekte in den BCa-Zelllinien wurde durch simultane Hemmung von BCL-XL und Survivin erzielt. Beispielsweise stieg der Anteil apoptotischer Zellen von 64 % nach Survivin-siRNA+Cisplatin-Behandlung auf 94 % nach gleichzeitiger BCL-XL+Survivin-Inhibition in Kombination mit Cisplatin. Folglich stellt die simultane Inhibition von BCL-XL und Survivin in Kombination mit Chemotherapeutika eine äußert viel versprechende BCa-Therapieoption dar. Tierexperimentelle Studien belegen die wachstumsinhibitorische Wirkung der Survivin-Reduktion und der kombinierten BCL-XL-siRNA+Chemotherapie-Behandlung, so wurde das Tumorendvolumen im Vergleich zur Kontrollbehandlung um 43 % bzw. um 48 % reduziert.

No description available.

The development of medicine and technology related to the level of healthcare as a whole is historically accompanied with changes in nursing practices that have increased their demands over the years. This caused a specific need for the diversification of nursing activities and their specialization. The aim of this work is to map out specialized nursing processes of the field of internal medicine from their formation to the present, showing healthcare as a progressive sector, where new knowledge and technologies induce the need for new activities that the medical nursing staff must manage for the benefit of the patient. This basic objective will be documented in selected specialized nursing care activities divided into three professional sections - development of oxygen therapy, catheterization of the bladder and venous blood collection. The basis for the diploma thesis is the development of specialization of nursing practices on the basis of economic, political, cultural or religious influence. The results of the research show that the development of nursing practices has been constantly changing since their inception, not only in connection with the development and availability of quality aids, but also by the effort to create the most effective nursing process with regard to the needs of the patient as well as the non-medical medical staff. The diploma thesis also shows the professional competencies that have been added to the general nurses in the context of time. In the first part, dealing with the development of oxygen therapy, there is considerable interconnection of this process with the war period. There was also a significant difference in the distinctions in competences in the provision of oxygen therapy to nurses in the Czech Republic and abroad. Despite the fact that the non-medical healthcare professionals is currently preparing and subsequently applying Oxygen treatment on their own, they can only do so on the basis of a doctor's office. In contrast, for example, in the 1930s, in the USA, the nurse was regulating the oxygen alone within its competencies. The second part of the diploma thesis was oriented on the characteristics of the development of bladder catheterization. Particularly in this section is the development of nursing competencies, as it was just bladder catheterization, which in history was the sole competence of an experienced physician. The diploma thesis demonstrates not only the development of the procedure, the aids, the reduction of risks accompanying this method, but also the gradual assistance of the non-medical medical staff until the definition of the period when they are fully competent to perform this task. The last part of the diploma thesis is focused on the development of venous blood collection in order to obtain sufficient quantity for blood analysis. In this area, is not onlz the development of the nursing process in connection with the technique or aids, but also the necessity of observing the aseptic approach. The result of the presented work represents a significant contribution, because only with the knowledge of nursing techniques in the whole range, people can avoid mistakes from history. Also, the view of the selected nursing practice in the context of time brings knowledge of the inactivity of development and is thus the undisputed motivation of non-medical health personnel to participate in the constant innovation of nursing practices and thus to deepen the specialization and level of nursing care.

Submitted by Ana Maria Fiscina Sampaio (fiscina@bahia.fiocruz.br) on 2012-08-02T21:38:04Z No. of bitstreams: 1 Raimundo Celestino Silva Neves. Prevalência e grau de desconforto de bexiga hiperativa numa área urbana no Nordeste brasileiro - CPqGM - Dissertação de Mestrado - 2008.pdf: 741822 bytes, checksum: 52611300a032353b413d569d677cd039 (MD5) / Made available in DSpace on 2012-08-02T21:38:04Z (GMT). No. of bitstreams: 1 Raimundo Celestino Silva Neves. Prevalência e grau de desconforto de bexiga hiperativa numa área urbana no Nordeste brasileiro - CPqGM - Dissertação de Mestrado - 2008.pdf: 741822 bytes, checksum: 52611300a032353b413d569d677cd039 (MD5) Previous issue date: 2008 / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, Bahia, Brasil / Estimar a prevalência da síndrome de bexiga hiperativa (BH) e de outros sintomas referentes ao trato urinário inferior em uma amostra com base populacional de um grande centro urbano do nordeste brasileiro. Adicionalmente, pretendeu-se avaliar o impacto desses sintomas na qualidade de vida dos participantes, investigar possíveis fatores associados à prevalência de BH e descrever a busca por tratamento para essa síndrome. Métodos: A prevalência de BH foi avaliada segundo sua definição mais recente, estabelecida em 2002 ,pela Sociedade Internacional de Continência (SIC) e o inquérito domiciliar utilizou o método de amostragem estratificado em três estágios, abrangendo 17 regiões administrativas da cidade de Salvador. Os resultados são apresentados de acordo o sexo e a faixa etária. Resultados: Três mil indivíduos com idade ≥ 30 anos foram incluídos no estudo, sendo 1.500 homens e 1.500 mulheres (taxa de resposta de 82,9%). A prevalência de BH foi de 5,1% em homens e 10% em mulheres. Nicturia (≥ 1 por noite) esteve presente em 64,4% dos homens e 71,2% das mulheres, enquanto que a prevalência de nictúria (≥2 por noite) foi de 33,3% e 36,5%, respectivamente. Já a freqüência urinária aumentada foi descrita por 15,4% dos homens e 23,7% das mulheres. A maioria das pessoas com urgência, 80% dos homens e 78% das mulheres, relatou algum grau de desconforto em possuir esse sintoma e indivíduos com BH tiveram alto grau de depressão e ansiedade (p<0,001). Conclusão: Esse é o maior estudo epidemiológico com base populacional no Brasil e que utiliza as novas definições referentes ao trato urinário inferior, recomendadas pela SIC em 2002. O incômodo provocado nos indivíduos, o impacto na qualidade de vida e a prevalência dos sintomas de BH destacam a gravidade dessa síndrome. / To estimate the prevalence of overactive bladder syndrome (OAB) and the other lower urinary tract symptoms (LUTS) in a sample of the big urban center in the Brazilian Northeastern. Additionally, to evaluate the impact of these symptoms in quality of life of participants, to investigate possible factors associates to the prevalence of OAB and to describe help seeking behaviors for urinary problems. Methods: The prevalence of OAB was evaluated according to your more recent definition established in 2002 for the International Continence Society (ICS) and the domiciliary inquiry used a three-step sampling method, enclosing 17 administrative regions of the city of Salvador. The results are presented according to gender and age cohort. Results: A total of three thousand individuals aged ≥ 30 years were analyzed in the study, (1,500 men and 1,500 women) with response rate of 82.9%. The prevalence of BH was 5.1% in men and 10% in women. Nocturia (≥ 1 time/ night) was present in 64.4% of men and 71.2% of the women, while that the prevalence of nocturia (≥ 2 time/ night) was 33.3% and 36.5%, respectively. However the increased frequency was described for 15,4% of men and 23.7% of the women. The majority of the people with urgency, 80% of men and 78% of the women, report any bother with symptom and OAB subjects had high level of depression and anxiety. Conclusion: This is the largest epidemiologic study with population-based in Brazil and that it uses the new definitions of the ICS of 2002. The bother provoked in the individuals, the impact in the quality of life and the prevalence of the LUTS salient the gravity of this syndrome.